Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
在市場動盪和不確定的時期，許多投資者會轉向股息收益股，這些通常是具有較高的自由現金流並以高紅利派息獎勵股東的公司。
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Benzinga讀者可以訪問分析師股票評級頁面，查看對他們最喜歡的股票的最新分析師評級。交易員可以整理Benzinga廣泛的分析師評級數據庫，包括按照分析師準確度進行整理。
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
以下是醫療保健板塊三隻高收益股票最準確的分析師評級。
Pfizer Inc. (NYSE:PFE)
輝瑞公司(NYSE:PFE)
Dividend Yield: 5.66%
股息收益率：5.66%
- Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating with a price target of $45 on Sept. 16. This analyst has an accuracy rate of 70%.
- Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $28 to $30 on July 31. This analyst has an accuracy rate of 78%.
- Recent News: Pfizer recently presented positive data from Phase 2 study of Ponsegromab in Patients with cancer cachexia.
- Benzinga Pro's real-time newsfeed alerted to latest PFE news.
- Cantor Fitzgerald分析師Louise Chen於9月16日重申對該股票的超配評級，目標股價爲45美元。該分析師的準確率爲70%。
- Wells Fargo分析師Mohit Bansal於7月31日維持持平評級，將目標股價從28美元上調至30美元。該分析師的準確率爲78%。
- 最新資訊：輝瑞最近發佈了關於在癌症惡病質患者中進行龐塞格羅馬布的2期研究的正面數據。
- Benzinga Pro的實時新聞提醒了最新的輝瑞（PFE）資訊。
CVS Health Corporation (NYSE:CVS)
西維斯健康公司（紐約證券交易所股票代碼：CVS）
- Dividend Yield: 4.55%
- RBC Capital analyst Ben Hendrix reiterated an Outperform rating with a price target of $68 on Sept. 4. This analyst has an accuracy rate of 74%
- Barclays analyst Andrew Mok maintained an Equal-Weight rating and cut the price target from $65 to $63 on Aug. 8. This analyst has an accuracy rate of 79%.
- Recent News: Wednesday, Oak Street Health, a subsidiary of CVS Health, agreed to settle for $60 million following allegations that it violated the False Claims Act.
- Benzinga Pro's charting tool helped identify the trend in CVS stock.
- 股息率：4.55%
- RBC Capital的分析師Ben Hendrix在9月4日重申了對該股的買入評級，目標價爲68美元。該分析師的準確率爲74%。
- 巴克萊銀行的分析師Andrew Mok在8月8日維持了均衡評級，將目標價格從65美元下調至63美元。該分析師的準確率爲79%。
- 最新消息：週三，西維斯健康旗下的Oak Street Health同意支付6000萬美元，以了結違反《虛假索賠法案》的指控。
- Benzinga Pro的圖表工具幫助識別了西維斯股票的趨勢。
Gilead Sciences, Inc. (NASDAQ:GILD)
吉利德科學股份有限公司（納斯達克股票代碼：GILD）
- Dividend Yield: 3.67%
- RBC Capital analyst Brian Abrahams maintained a Sector Perform rating and raised the price target from $72 to $74 on Sept. 4. This analyst has an accuracy rate of 65%.
- Needham analyst Joseph Stringer reiterated a Hold rating on Aug. 15. This analyst has an accuracy rate of 80%.
- Recent News: Gilead Sciences, last week, revealed the results of an interim analysis from a second Phase 3 trial investigating the use of the company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir.
- Benzinga Pro's signals feature notified of a potential breakout in GILD shares.
- 股息率：3.67%
- RBC Capital分析師Brian Abrahams維持持有評級，並於9月4日將價格目標從72萬億美元提高到74美元。該分析師的準確率爲65%。
- Needham分析師Joseph Stringer在8月15日重申持有評級。該分析師的準確率爲80%。
- 近期資訊：吉利德科學（Gilead Sciences）上週公佈了第二期3期試驗的中期分析結果，該試驗調查了該公司每年兩次注射的HIV-1衣殼抑制劑lenacapavir的使用。
- Benzinga Pro的信號功能提醒GILD股票可能出現突破。
Read More:
閱讀更多：
- Nvidia, Tesla Rally As Dow, S&P 500 Surge To Fresh Highs After Fed Cuts Rates: Fear Index Remains In 'Greed' Zone
- 英偉達、特斯拉股價上漲，道瓊斯指數、標準普爾500指數在聯邦減息後刷新新高：恐懼指數仍處於「貪婪」區域
譯文內容由第三人軟體翻譯。